Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. (OpticSkin)

February 9, 2026 updated by: Centre Hospitalier Régional Metz-Thionville
Skin carcinomas are the most commonly diagnosed cancers in fair-skinned populations, for example in France, Western Europe, and North America in particular. The OpticSkin project will build and make available to the general public and the scientific and medical community a histological and optical spectroscopic database of healthy, precancerous, and cancerous human skin in terms of absorption, elastic and inelastic scattering (Raman), steady-state and time-resolved autofluorescence, and polarization. The aim is to identify spectroscopic signatures that will be useful for diagnosis.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

The Priority Research Program and Equipment for Light-Matter (PEPR LUMA) has granted its support to the OpitcSkin project, which aims to provide diagnostic information that complements that currently provided by histology for the diagnosis of skin carcinomas, the most common cancers among fair-skinned populations. In recent years, several imaging and optical spectroscopy modalities have been evaluated in vivo in clinical settings to quantify the real-time diagnostic assistance they provide to clinicians performing surgical resection of skin carcinomas. Imaging methods such as confocal reflectance microscopy, optical coherence tomography, and nonlinear optical microscopy provide morphological information that improves diagnostic accuracy and reduces the risk of recurrence by allowing immediate verification after surgery that the tumor has been completely removed.

Spectroscopic methods, including Raman spectroscopy and autofluorescence, which are also applied in vivo, provide additional structural and functional information, for example on metabolism, further improving diagnostic accuracy. In all cases, studies have shown that combining multiple optical imaging and/or spectroscopy modalities, as well as data analysis and/or machine learning methods, offers better diagnostic accuracy than each modality taken individually.

Study Type

Observational

Enrollment (Estimated)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
    • France
      • Metz, France, France, 57085
        • CHR Metz-Thionville

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The OpticSkin study will be conducted on paraffin blocks containing skin samples taken from the 140 patients included in the SpectroLive study NCT0295626, ID-RCB: 2016-A00608-43.

Description

Inclusion Criteria:

  • patients with skin carcinomas and actinic keratoses

Exclusion Criteria:

  • minor patient

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
automated recognition
Time Frame: Until the end of the study on average 2 years
automated recognition (by supervised classification) of optical data acquired on different histological classes
Until the end of the study on average 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Régional Metz-Thionville

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria

February 9, 2026

First Posted (Actual)

February 12, 2026

Study Record Updates

Last Update Posted (Actual)

February 12, 2026

Last Update Submitted That Met QC Criteria

February 9, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-08-Obs-CHRMT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Skin Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe